Refine Search

New Search

Advanced search

Journal Transplantation Journal

-
62,743 articles
Page of 6,275
Articles per Page
by
Show export options
  Select all
Amy Cross, Fadi Issa
Transplantation Journal, Volume 103, pp 2453-2454; doi:10.1097/tp.0000000000003009

Jakub Kristek, Liza Johannesson, Giuliano Testa, Roman Chmel, Michael Olausson, Niclas Kvarnström, Nikolaos Karydis, Jiri Fronek
Transplantation Journal, Volume 103, pp 2449-2452; doi:10.1097/tp.0000000000002830

Haoda Yu, Tao Bian, Zhen Yu, Yiping Wei, Jianjun Xu, Jianrong Zhu, Wenxiong Zhang
Transplantation Journal, Volume 103, pp 2634-2644; doi:10.1097/tp.0000000000002841

The publisher has not yet granted permission to display this abstract.
Anne M. Halpin, Susan Nahirniak, Patricia M. Campbell, Simon Urschel, Daniel H. Kim, Lori J. West, Tara Pidorochynski, Holger Buchholz, Jennifer Conway
Transplantation Journal, Volume 103, pp 2715-2724; doi:10.1097/tp.0000000000002798

The publisher has not yet granted permission to display this abstract.
Jordan M. Chiasson, Cory E. Fominaya, Mulugeta Gebregziabher, David J. Taber
Transplantation Journal, Volume 103, pp 2675-2681; doi:10.1097/tp.0000000000002689

The publisher has not yet granted permission to display this abstract.
Ashley A. Vo, Olivier Aubert, Mark Haas, Edmund Huang, Xiaohai Zhang, Jua Choi, Alice Peng, Reiad Najjar, Supreet Sethi, Nori Ammerman, et al.
Transplantation Journal, Volume 103, pp 2666-2674; doi:10.1097/tp.0000000000002691

Abstract:Highly-HLA sensitized patients (HS) have an increased risk for development of donor specific antibodies (DSA) and antibody-mediated rejection (ABMR) post-transplant. Here we examined the risk for ABMR in HS patients transplanted after desensitization (DES) who were DSA+ v. DSA- at transplant.We also examined the incidence and clinical impact of de novo DSAs (dnDSAs) and compared to dnDSA- patients. From January 2013 - October 2016, 90 HS patients (PRA>80%, DSA+ = 50 v. DSA- = 40) received kidney transplantation after DES with IVIG + rituximab ± PLEX ± tocilizumab.DSAs were monitored at transplant, 1, 3, 6, 12, 24, 36 & 48M post-transplant. Patients were divided into 4 groups: DSA+/+ (n= 31), DSA+/- (n=19), DSA-/+ (n=10); and DSA-/- (n=30).Median follow up time was 2.9 years.DSA negative patients who developed dnDSA had the highest incidence of ABMR (70%) compared to the DSA+/+ (45%), DSA+/- (11%) and DSA-/- (10%) patients (p<0.0001). Among patients who developed ABMR, Banff 2013 ABMR scores did not differ among the 4 groups. Graft survival and eGFR determinations at 4 years were similar. Persistence of preexisting DSAs or development of dnDSA after transplant is associated with an increased risk for ABMR.Despite this, we did not observe a difference in Banff biopsy scores, graft survival or patient survival compared to those without DSAs after transplant.Thus, for HS patients undergoing HLAi kidney transplant, desensitization therapy and frequent monitoring for dnDSAs appears critical for good long-term survival in at risk groups.This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Megan A. Adams, Margret E. Bock, Jens Goebel
Transplantation Journal, Volume 103, pp 2458-2459; doi:10.1097/tp.0000000000002705

Elisabet Van Loon, Maarten Naesens
Transplantation Journal, Volume 103, pp 2464-2465; doi:10.1097/tp.0000000000002661

Manish Suneja, Sarat Kuppachi, Daniel Katz, Lawrence Hunsicker
Transplantation Journal, Volume 103, pp 2549-2557; doi:10.1097/tp.0000000000002706

The publisher has not yet granted permission to display this abstract.
Maria Meneghini, Oriol Bestard
Transplantation Journal, Volume 103, pp 2466-2467; doi:10.1097/tp.0000000000002660

Page of 6,275
Articles per Page
by
Show export options
  Select all